Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 6/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TYR | P14679 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6014787 | 0.80 | KDM5B (0.34) | HCAR2 | |
| SCHEMBL68054 | 0.77 | IDO1 (0.33) | — | |
| SCHEMBL22478334 | 0.76 | PLA2G4A (0.33) | FAAHMAPTGABRB2 | |
| SCHEMBL27378739 | 0.74 | TYR (0.37) | ALOX5PTGS2LIPGHCAR3HCAR2 | |
| SCHEMBL370841 | 0.74 | TDP1 (0.35) | ALOX5PTGS2LIPGHCAR3HCAR2 | |
| SCHEMBL22276441 | 0.74 | — | — | |
| SCHEMBL544780 | 0.73 | TLR8 (0.42) | — | |
| SCHEMBL1880278 | 0.73 | ALOX5 (0.44) | ALOX5PTGS2LIPGHCAR3HCAR2 | |
| SCHEMBL31013116 | 0.73 | TYR (0.40) | ALOX5PTGS2LIPGHCAR2MEN1 | |
| SCHEMBL27671187 | 0.73 | LIPG (0.38) | ALOX5PTGS2LIPGHCAR2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2501407-A1 | ANTI-ORAI1 ANTIGEN BINDING PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20120231006-A1 | ANTI-ORAI1 ANTIGEN BINDING PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2012-09-13 | — | — | US | disclosed |
| WO-2011063277-A1 | ANTI-ORAI1 ANTIGEN BINDING PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120231006-A1 | ANTI-ORAI1 ANTIGEN BINDING PROTEINS AND USES THEREOF | STIM2, ORAI2, STIM1 | ALOX5 3770/4885PTGS2 1866/4885LIPG 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.